184 related articles for article (PubMed ID: 38086946)
1. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract][Full Text] [Related]
2. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
[TBL] [Abstract][Full Text] [Related]
3. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
4. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
6. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Marchesini M; Gherli A; Simoncini E; Tor LMD; Montanaro A; Thongon N; Vento F; Liverani C; Cerretani E; D'Antuono A; Pagliaro L; Zamponi R; Spadazzi C; Follini E; Cambò B; Giaimo M; Falco A; Sammarelli G; Todaro G; Bonomini S; Adami V; Piazza S; Corbo C; Lorusso B; Mezzasoma F; Lagrasta CAM; Martelli MP; La Starza R; Cuneo A; Aversa F; Mecucci C; Quaini F; Colla S; Roti G
Nat Commun; 2024 Jun; 15(1):4739. PubMed ID: 38834613
[TBL] [Abstract][Full Text] [Related]
7. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
8. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
10. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
11. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
12. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
13. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract][Full Text] [Related]
14. A critical role of epigenetic inactivation of miR-9 in EVI1
Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
[TBL] [Abstract][Full Text] [Related]
15. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
[TBL] [Abstract][Full Text] [Related]
16. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
[TBL] [Abstract][Full Text] [Related]
17. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
18. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
19. [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].
He XF; Wang QR; Cen JN; Qiu HY; Sun AN; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):936-941. PubMed ID: 27995876
[TBL] [Abstract][Full Text] [Related]
20. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
